[go: up one dir, main page]

AU6946300A - Use of dna encoding osteoprotegerin to prevent or inhibit metabolic bone disorders - Google Patents

Use of dna encoding osteoprotegerin to prevent or inhibit metabolic bone disorders

Info

Publication number
AU6946300A
AU6946300A AU69463/00A AU6946300A AU6946300A AU 6946300 A AU6946300 A AU 6946300A AU 69463/00 A AU69463/00 A AU 69463/00A AU 6946300 A AU6946300 A AU 6946300A AU 6946300 A AU6946300 A AU 6946300A
Authority
AU
Australia
Prior art keywords
prevent
dna encoding
bone disorders
metabolic bone
inhibit metabolic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU69463/00A
Inventor
Patrick M. Doran
Sundeep Khosla
B. Lawrence Riggs
Stephen T. Russel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Clinic in Florida
Original Assignee
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research, Mayo Clinic in Florida filed Critical Mayo Foundation for Medical Education and Research
Publication of AU6946300A publication Critical patent/AU6946300A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU69463/00A 1999-08-30 2000-08-29 Use of dna encoding osteoprotegerin to prevent or inhibit metabolic bone disorders Abandoned AU6946300A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15141599P 1999-08-30 1999-08-30
US60151415 1999-08-30
PCT/US2000/023755 WO2001016299A1 (en) 1999-08-30 2000-08-30 Use of dna encoding osteoprotegerin to prevent or inhibit metabolic bone disorders

Publications (1)

Publication Number Publication Date
AU6946300A true AU6946300A (en) 2001-03-26

Family

ID=22538668

Family Applications (1)

Application Number Title Priority Date Filing Date
AU69463/00A Abandoned AU6946300A (en) 1999-08-30 2000-08-29 Use of dna encoding osteoprotegerin to prevent or inhibit metabolic bone disorders

Country Status (3)

Country Link
AU (1) AU6946300A (en)
CA (1) CA2383043A1 (en)
WO (1) WO2001016299A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE01973455T1 (en) 2000-09-22 2004-04-22 Immunex Corp., Seattle SCREENING PROCEDURE FOR AGONISTS AND ANTAGONISTS OF THE RECEPTOR ACTIVATOR OF NF-KAPPA B
AU2002253133B2 (en) * 2001-04-03 2008-02-28 Societe Des Produits Nestle S.A. Osteoprotegerin in milk
KR100427299B1 (en) * 2001-08-10 2004-04-14 한국생명공학연구원 Recombination plasmid pGHOPG(KCTC 1019BP) to produce human osteoprotegerin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin

Also Published As

Publication number Publication date
WO2001016299A1 (en) 2001-03-08
CA2383043A1 (en) 2001-03-08

Similar Documents

Publication Publication Date Title
AU5125400A (en) Methods for managing the distribution of client bits to client computers
EP1542720A4 (en) Treatment of tnf alpha related disorders
AU2111500A (en) Bone tissue regenerating composition
AU2001242450A1 (en) Substances for the treatment of spinal muscular atrophy
AU4248000A (en) Methods of use of the taci/taci-l interaction
AU7888801A (en) Use of 2-methylene-19-nor-20(s)-1alpha,25-dihydroxyvitamin D<sub>3</sub> to increase bone strength
IL155433A0 (en) Treatment of t cell disorders
AU2001266225A1 (en) Decondensation of dna
AU3110500A (en) Cell matrix plaques of initial bone formation
AU2001256555A1 (en) New inhibotor of apoptosis of nerve cells
AU6946300A (en) Use of dna encoding osteoprotegerin to prevent or inhibit metabolic bone disorders
AU7104500A (en) Use of rafp to inhibit or prevent apoptosis
AU2003268484A1 (en) Delivery of therapeutics to the brain and spinal cord
AU2003239864A1 (en) Antisense moodulation of kinesin-like 1 expression
AU2002246926A1 (en) 12-hydroxy-eicosatrienoic acid analogs and methods of use thereof
AU7123101A (en) New spinal system
PL363921A1 (en) Skin moisturizing composition
GB0003048D0 (en) The therapeutic use of polysulphonated polyglycosides or other polyanionic compounds in autism
AU4036199A (en) Stabilised compositions containing hyaluronic acid, their preparation and use
AU2003240446A1 (en) Use of mob-5 in pain
AU2003223070A1 (en) Obg3 fragments inhibiting the conversion of active obg3 into less active obg3 and other compositions for treatment of metabolic disorders
AU2001233246A1 (en) Novel use of ribozymes to block gene expression
AU1354201A (en) Compositions and methods of synthesis and use of novel nucleic acid structures
AU2001255998A1 (en) Treatmentor prevention of metabolic bone disorder
AU2001253219A1 (en) Composition for treatment of autoimmune disease

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase